Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 11.88 as of 2026-10-06T21:34:21.185Z.
Consensus retrieved: 2026-10-06T17:32:28.855Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:34:21.185Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 674af8cde1417d6ea5357272f49486250de5c59c0a8be43bfb1ee673b50916f0
Forward PE Ratio (11.88) = Dated Quote Price ($2.02) / Consensus Forward EPS ($0.17)
FORWARD PE RATIO
11.88
SECTOR MEDIAN · HEALTHCARE
19.75
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
-39.85%
vs the sector median at left
TherapeuticsMD, Inc.
Market Cap
$23.38M
Forward PE Ratio
11.88
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | $23.38M | 11.88 |
| Rein Therapeutics Inc. (RNTX)vs › | $23.06M | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.68M | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.13M | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A |
| Modular Medical, Inc. (MODD)vs › | $22.25M | N/A |
| InspireMD, Inc. (NSPR)vs › | $24.60M | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.00M | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $25.22M | N/A |
| NextCure, Inc. (NXTC)vs › | $20.53M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
11.9
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.02, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.17 | $0.17 – $0.17 | 1 | 11.9x |
| 2027-12-31 | $0.19 | $0.19 – $0.19 | 1 | 10.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
